Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Human Pathology|December 14, 2011
Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsyAshley Cimino-Mathews, Jessica L Hicks, Peter B Illei, et al.
Human Pathology|December 25, 2012
Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomasAshley Cimino-Mathews, Andrea P Subhawong, Hillary Elwood, et al.
JAMA Oncology|January 8, 2026
Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid TumorsDerek Shyr, Yash Pershad, Kun Zhao, et al.
Breast Cancer Research : BCR|April 19, 2019
BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cellsXiaowen Zhang, Yao Wang, Huai-Chin Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2013
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model systemJulia A Beaver, John P Gustin, Kyung H Yi, et al.
Human Pathology|February 5, 2013
GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomasAshley Cimino-Mathews, Andrea P Subhawong, Peter B Illei, et al.
Cancer Research|October 22, 2009
Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cellsMichele I Vitolo, Michele B Weiss, Marta Szmacinski, et al.
Clinical & Experimental Metastasis|June 14, 2012
The role of targeted therapy and biomarkers in breast cancer treatmentAlison T Stopeck, Ursa Brown-Glaberman, Hong Yuen Wong, et al.
Cancer Biology & Therapy|January 17, 2004
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cellsKurtis E Bachman, Brian G Blair, Keith Brenner, et al.
Oncotarget|November 16, 2017
ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibitionGary K Scott, David Chu, Ravneet Kaur, et al.
Pageof 12